이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

NanJing Pharmaceutical 관리

관리 기준 확인 2/4

NanJing Pharmaceutical's CEO는 Liang Zhang, Apr2022 에 임명되었습니다 의 임기는 2.17 년입니다. 는 CN¥ 712.00K 가치에 해당하는 회사 주식의 0.012% 직접 소유합니다. 712.00K. 경영진과 이사회의 평균 재임 기간은 각각 9.8 년과 4.2 년입니다.

주요 정보

Liang Zhang

최고 경영자

CN¥2.1m

총 보상

CEO 급여 비율	n/a
CEO 임기	2.5yrs
CEO 소유권	0.01%
경영진 평균 재임 기간	10.2yrs
이사회 평균 재임 기간	4.5yrs

최근 관리 업데이트

Recent updates

Returns On Capital At NanJing Pharmaceutical (SHSE:600713) Paint A Concerning Picture

Sep 26

CEO

Liang Zhang (51 yo)

2.5yrs

테뉴어

CN¥2,103,500

보상

Mr. Liang Zhang is President and Director of NanJing Pharmaceutical Company Limited from April 28, 2022.

리더십 팀

이름	위치	테뉴어	보상	소유권
Liang Zhang	President & Director	2.5yrs	CN¥2.10m	0.012% CN¥ 804.8k
Jian Sun	Chief Accountant & CFO	12.5yrs	CN¥1.25m	0.012% CN¥ 804.8k
Xun Jie Luo	VP & Director	no data	CN¥1.41m	데이터 없음
Hong Xiao	Vice President	no data	CN¥1.22m	0.018% CN¥ 1.2m
Yuping Peng	Vice President	no data	CN¥1.08m	0.017% CN¥ 1.1m
Wen Jun Li	VP & Secretary of the Board of Directors	10.2yrs	CN¥1.51m	0.020% CN¥ 1.3m
Jian Zhong Tang	Vice President	no data	CN¥1.53m	0.020% CN¥ 1.3m
Chuang Feng	Vice President	no data	CN¥1.51m	0.020% CN¥ 1.3m
Qing Yang	Chief Auditor & Member of Supervisory Board	no data	CN¥501.30k	데이터 없음
Xia Yao	Employee Supervisor & VP	no data	CN¥1.34m	데이터 없음

10.2yrs

평균 재임 기간

51.5yo

평균 연령

경험이 풍부한 관리: 600713 의 관리팀은 노련하고 경험 (평균 재직 기간 9.8 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Liang Zhang	President & Director	2.5yrs	CN¥2.10m	0.012% CN¥ 804.8k
Xun Jie Luo	VP & Director	7.2yrs	CN¥1.41m	데이터 없음
Qing Yang	Chief Auditor & Member of Supervisory Board	12.8yrs	CN¥501.30k	데이터 없음
Xia Yao	Employee Supervisor & VP	5.6yrs	CN¥1.34m	데이터 없음
Jian Jun Zhou	Chairman	9.8yrs	CN¥2.19m	0.028% CN¥ 1.9m
Zhigang Hu	Independent Director	6.5yrs	CN¥120.00k	데이터 없음
Yindi Lu	Independent Director	2.5yrs	CN¥120.00k	데이터 없음
Jiannan Xu	Director	3.5yrs	CN¥1.79m	0.020% CN¥ 1.3m
Marco Kerschen	Director	3.1yrs	데이터 없음	데이터 없음
Chunhui Wang	Independent Director	2.5yrs	CN¥120.00k	데이터 없음

4.5yrs

평균 재임 기간

52yo

평균 연령

경험이 풍부한 이사회: 600713 의 이사회는 경험(평균 재직 기간 4.2 년)으로 간주됩니다.

NanJing Pharmaceutical 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

NanJing Pharmaceutical Company Limited, Annual General Meeting, May 31, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

NanJing Pharmaceutical Company Limited to Report Q3, 2024 Results on Oct 31, 2024

Investor sentiment improves as stock rises 19%

Returns On Capital At NanJing Pharmaceutical (SHSE:600713) Paint A Concerning Picture

Second quarter 2024 earnings released: EPS: CN¥0.12 (vs CN¥0.12 in 2Q 2023)

NanJing Pharmaceutical Company Limited to Report First Half, 2024 Results on Aug 30, 2024

NanJing Pharmaceutical Company Limited, Annual General Meeting, May 31, 2024

Full year 2023 earnings released: EPS: CN¥0.45 (vs CN¥0.47 in FY 2022)

NanJing Pharmaceutical Company Limited to Report Q1, 2024 Results on Apr 30, 2024

NanJing Pharmaceutical Company Limited to Report Fiscal Year 2023 Results on Apr 08, 2024

Third quarter 2023 earnings released: EPS: CN¥0.10 (vs CN¥0.11 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.12 (vs CN¥0.16 in 2Q 2022)

Investor sentiment improves as stock rises 16%

Full year 2022 earnings released: EPS: CN¥0.47 (vs CN¥0.48 in FY 2021)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.11 (vs CN¥0.12 in 3Q 2021)

Third quarter 2022 earnings released: EPS: CN¥0.11 (vs CN¥0.12 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.16 (vs CN¥0.12 in 2Q 2021)

First quarter 2022 earnings released: EPS: CN¥0.11 (vs CN¥0.098 in 1Q 2021)

Less than half of directors are independent

Full year 2021 earnings released: EPS: CN¥0.48 (vs CN¥0.36 in FY 2020)

Third quarter 2021 earnings released: EPS CN¥0.12 (vs CN¥0.11 in 3Q 2020)

NanJing Pharmaceutical Company Limited announced that it expects to receive CNY 999.999998 million in funding from Nanjing XinGong Investment Group Co., Ltd

Second quarter 2021 earnings released: EPS CN¥0.12 (vs CN¥0.093 in 2Q 2020)

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.098 (vs CN¥0.073 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.36 (vs CN¥0.33 in FY 2019)

NanJing Pharmaceutical Company Limited to Report Fiscal Year 2020 Results on Mar 27, 2021

New 90-day low: CN¥4.06

New 90-day low: CN¥4.29

Third quarter earnings released

New 90-day low: CN¥4.52

Earnings released

New 90-day high - CN¥5.10

NanJing Pharmaceutical Company Limited to Report First Half, 2020 Results on Aug 22, 2020

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령